Substitution-Modulated Anticancer Activity of Half-Sandwich Ruthenium(II) Complexes with Heterocyclic Ancillary Ligands

Crystal Structures of Half-Sandwich Ru(II) Complexes, [(η6-p-Cymene)(3-chloro-6-(1H-pyrazol-1-yl)pyridazine)Ru(X)]BF4, (X = Cl, Br, I)

Herein, we report the synthesis and single-crystal X-ray structures of three (η6-p-cymene)Ru(II) tetrafluoroborate salts, viz., [(η6-p-cymene)(3-chloro-6-(1H-pyrazol-1-yl)pyridazine)Ru(X)]BF4, (X = Cl, Br, I), Ru1-3. They were prepared by the reactions of [(η6-p-cymene)Ru(μ-X)(X)]2, (X = Cl, Br, I) with two-mole equivalents of 3-chloro-6-(1H-pyrazol-1-yl)pyridazine, under inert conditions at ambient temperatures, and subsequently precipitated by the addition of excess BF4− ions. Orange crystalline precipitates were obtained in good yields, from which the respective single crystals for X-ray diffraction analysis were recrystallized by slow evaporation from their methanolic/diethyl ether solutions. The Ru(II) complexes were characterized by various spectroscopic techniques and chemical methods, which included FTIR, 1H/13C NMR, UV-visible absorption, mass spectrometry, and elemental analysis. The molecular structures were solved by single-crystal X-ray crystal diffraction analysis. The complexes crystallized in the monoclinic crystal system in the P21/c (Ru1-2) and P21/n (Ru3) space groups. Density Functionals Theoretical (DFT) calculations were performed in methanol to gain an understanding of the electronic and structural properties of the complexes. Trends in the data metrics were established, and selected data were compared with the diffraction data. The electrophilicity indices of Ru1-3 follow the order Ru3 > Ru2 > Ru1, and the trend is in line with their anticipated order of reactivity towards nucleophiles.

Five-Membered Ruthenacycles: Ligand-Assisted Alkyne Insertion into 1,3-N,S-Chelated Ruthenium Borate Species

Building upon previous work, the chemistry of [(η⁶ -p-cymene)Ru{P(OMe)₂ OR}Cl₂ ], (R=H or Me) has been extended with [H₂ B(mbz)₂ ]^- (mbz=2-mercaptobenzothiazolyl) using different Ru precursors and borate ligands. As a result, a series of 1,3-N,S-chelated ruthenium borate complexes, for example, [(κ² -N,S-L)PR₃ Ru{κ³ -H,S,S'-H₂ B(L)₂ }], (2 a-d and 2 a'-d'; R=Ph, Cy, OMe or OPh and L=C₅ H₄ NS or C₇ H₄ NS₂ ) and [Ru{κ³ -H,S,S'-H₂ B(L)₂ }₂ ], (3: L=C₅ H₄ NS, 3': L=C₇ H₄ NS₂ ) were isolated upon treatment of [(η⁶ -p-cymene)RuCl₂ PR₃ ], 1 a-d (R=Ph, Cy, OMe or OPh) with [H₂ B(mp)₂ ]^- or [H₂ B(mbz)₂ ]^- ligands (mp=2-mercaptopyridyl). All the Ru borate complexes, 2 a-d and 2 a'-d' are stabilized by phosphine/phosphite and hemilabile N,S-chelating ligands. Treatment of these Ru borate species, 2 a'-c' with various terminal alkynes yielded two different types of five-membered ruthenacycle species, namely [PR₃ {C₇ H₄ S₂ -(E)-N-C=CH(R')}Ru{κ³ -H,S,S'-H₂ B(L)₂ }], (4-4'; R=Ph and R'=CO₂ Me or C₆ H₄ NO₂ ; L=C₇ H₄ NS₂ ) and [PR₃ {C₇ H₄ NS-(E)-S-C=CH(R')}Ru{κ³ -H,S,S'-H₂ B(L)₂ }], (5-5', 6 and 7; R=Ph, Cy or OMe and R'=CO₂ Me or C₆ H₄ NO₂ ; L=C₇ H₄ NS₂ ). All these five-membered ruthenacycle species contain an exocyclic C=C moiety, presumably formed by the insertion of a terminal alkyne into the Ru-N and Ru-S bonds. The new species have been characterized spectroscopically and the structures were further confirmed by single-crystal X-ray diffraction analysis. Theoretical studies and chemical-bonding analyses established that charge transfer occurs from phosphorus to ruthenium center following the trend PCy₃ <PPh₃ <P(OPh)₃ <P(OMe)₃ .

Metal-free C-H mercaptalization of benzothiazoles and benzoxazoles using 1,3-propanedithiol as thiol source

A facile and effective C-H functionalization strategy for the synthesis of 2-mercaptobenzothiazoles and 2-mercaptobenzoxazoles is described. 1,3-Propanedithiol was employed to convert benzothiazoles and benzoxazoles to the corresponding heteroarylthiols in the presence of potassium hydroxide and DMSO. This novel protocol is featured by direct C-H mercaptalization of heteroarenes and a simple reaction system.

Lipophilicity-antiproliferative activity relationship study leads to the preparation of a ruthenium(II) arene complex with considerable in vitro cytotoxicity against cancer cells and a lower in vivo toxicity in zebrafish embryos than clinically approved cis-platin

Ru(II)-arene complexes are attracting increasing attention due to their considerable antitumoral activity. However, it is difficult to clearly establish a direct relationship between their structure and antiproliferative activity, as substantial structural changes might not only affect their anticancer activity but also tightly control their activation site(s) and/or their biological target(s). Herein, we describe the synthesis and characterization of four ruthenium(II) arene complexes bearing bidentate N,O-donor Schiff-base ligands ([Ru(η⁶-benzene)(N-O)Cl]) that display a significantly distinct antiproliferative activity against cancer cells, despite their close structural similarity. Furthermore, we suggest there is a link between their respective antiproliferative activity and their lipophilicity, as the latter affects their ability to accumulate into cancer cells. This lipophilicity-cytotoxicity relationship was exploited to design another structurally related ruthenium complex with a much higher antiproliferative activity (IC₅₀ > 25.0 μM) against three different human cancer cell lines. Whereas this complex shows a slightly lower activity than that of clinically approved cis-platin against the same human cancer cell lines, it displays a lower toxicity in zebrafish (Danio rerio) embryos at concentrations up to 20 μM.

Ruthenium(ii) p-cymene complexes of a benzimidazole-based ligand capable of VEGFR2 inhibition: hydrolysis, reactivity and cytotoxicity studies

Ru(ii)-p-Cymene complexes of a bispyrazole-benzimidazole ligand inhibit vascular endothelial growth factor 2, reduce the cellular glutathione pool and inhibit cell migration.

Crystal structure of N′-(2-phenylacetyl)thiophene-2-carbohydrazide monohydrate, C13H14N2O3S

C13H14N2O3S, monoclinic, C2/c (no. 15), a = 27.9910(12) Å, b = 6.5721(3) Å, c = 14.2821(7) Å, β = 92.600(3)°, V = 2624.6(2) Å3, Z = 8, R gt(F) = 0.042, wR ref(F 2) = 0.105, T = 100 K.

Fine tuning through valence bond tautomerization of ancillary ligands in ruthenium(ii) arene complexes for better anticancer activity and enzyme inhibition properties

Novel valence tautomerized ancillary ligand induce antiproliferative activity in ruthenium complex.